Abstract:Background: There is an observed variation in the burden of hepatocellular carcinoma (HCC) across different US populations. Our study aims to comprehensively assess variations in HCC incidence and mortality rates across different regions of the US. Understanding these geographical differences is crucial, given prior evidence indicating variations in the incidence of viral hepatitis and metabolic dysfunction-associated steatotic liver disease and varying access to curative HCC treatment among states. Methods: HCC age-adjusted incidence rates between 2001 and 2021 were obtained from the United States Cancer Statistics (USCS) database (which covers approximately 98% of the US population). HCC age-adjusted mortality rates between 2000 and 2022 were obtained from the National Center of Health Statistics (NCHS) database (covering approximately 100% of the US population). The rates were categorized by US geographical region into West, Midwest, Northeast, and South. Incidence rates were also categorized by race/ethnicity. Time trends [annual percentage change (APC) and average APC (AAPC)] were estimated by using Joinpoint Regression via the weighted Bayesian Information Criteria (p < 0.05). Results: Between 2001 and 2021, there were 491,039 patients diagnosed with HCC in the US (74.2% males). The highest incidence rate per 100,000 population was noted in the West (7.38), followed by the South (6.85). Overall incidence rates increased between 2001 and 2015 and then significantly decreased until 2021 (APC = -2.29). Most cases were in the South (38.8%), which also had the greatest increase in incidence (AAPC = 2.74). All four geographical regions exhibited an overall similar trend with an increase in incidence over the first 10-15 years followed by stable or decreasing rates. While stratification of the trends by race/ethnicity showed slight variations among the regions and groups, the findings are largely similar to all race/ethnic groups combined. Between 2000 and 2022, there were 370,450 patients whose death was attributed to HCC in the US (71.6% males). The highest mortality rate per 100,000 population was noted in the South (5.02), followed by the West (4.99). Overall mortality rates significantly increased between 2000 and 2013 (APC = 1.90), then stabilized between 2013 and 2016, and then significantly decreased till 2022 (APC = -1.59). Most deaths occurred in the South (35.8%), which also had the greatest increase in mortality (AAPC = 1.33). All four geographical regions followed an overall similar trend, with an increase in mortality over the first 10-15 years, followed by stable or decreasing rates. Conclusions: Our analysis, capturing about 98% of the US population, demonstrates an increase in HCC incidence and mortality rates in all geographical regions from 2000 to around 2014-2016, followed by stabilizing and decreasing incidence and mortality rates. We observed regional variations, with the highest incidence and mortality rates noted in the West and South regions and the fastest increase in both incidence and mortality noted in the South. Our findings are likely attributable to the introduction of antiviral therapy. Furthermore, demographic, socioeconomic, and comorbid variability across geographical regions in the US might also play a role in the observed trends. We provide important epidemiologic data for HCC in the US, prompting further studies to investigate the underlying factors responsible for the observed regional variations in HCC incidence and mortality.

Association of county‐level provider density with hepatobiliary cancer incidence and mortality

Association of county-level provider density and social vulnerability with colorectal cancer-related mortality

The Association of Oncology Provider Density With Black-White Disparities in Cancer Mortality in US Counties

Primary Care Physician Density and Mortality in the United States

The Influence of Residential Segregation, Urbanicity, and Population Density on Hepatocellular Carcinoma Incidence among a Low Socioeconomic Population

Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets

Most deprived Louisiana census tracts have higher hepatocellular carcinoma incidence and worse survival

Population-based risk factors and resource utilization for HCC: US perspective

The effect of obesity in hospitalized patients with hepatocellular carcinoma: A nationwide analysis.

Patterns of care and outcomes for hepatocellular carcinoma and pancreatic cancer based on rurality of patient's residence in a rural midwestern state

Favorable Mortality-to-Incidence Ratio Trends of Lung Cancer in Countries with High Computed Tomography Density

Burden of Hepatocellular Carcinoma and Pattern of Hepatitis B and C Presentation among HCC Patients: A Retrospective Study from a Tertiary Care Hospital in Karachi, Pakistan

Abstract A054 Liver cancer mortality by structural disadvantage and race: An analysis of U.S. area-level factors

Hepatocellular Carcinoma-Related Mortality in the USA, 1999–2018

Exploring disparities in palliative care utilization among hospitalized patients with hepatocellular carcinoma: A retrospective cohort study.

DISP-06. EXAMINING THE INFLUENCE OF NEUROSURGICAL ONCOLOGY PROVIDER ACCESS ON DIFFUSE GLIOMA SURVIVAL OUTCOMES: A NATIONWIDE COUNTY-LEVEL APPROACH

The impact of deprivation on colorectal cancer-stage distribution in a setting with high hospital bed density: A Japanese multilevel study

Hepatocellular Carcinoma Incidence and Mortality in the USA by Sex, Age, and Race: A Nationwide Analysis of Two Decades

Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study

Burden of liver cancer due to hepatitis C from 1990 to 2019 at the global, regional, and national levels

IDDF2020-ABS-0156 Association Between Incidence and Risk Factors of Liver Cancer: a Global Country-Level Analysis